<DOC>
	<DOCNO>NCT01183767</DOCNO>
	<brief_summary>The aim multicentre , prospective , double blind , placebo control , randomize pilot study investigate safety tolerance Epigallocatechin-Gallate ( EGCG , major polyphenol green tea ) patient muscular dystrophy Duchenne type . In second step investigator want investigate effect EGCG course Duchenne condition .</brief_summary>
	<brief_title>Sunphenon Epigallocatechin-Gallate ( EGCg ) Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>Duchenne muscular dystrophy ( DMD ) frequent neuromuscular condition occur childhood youth . The course disease progressive , life expectancy severely curtailed participation respiratory muscle and/or progressive cardiomyopathy . DMD derive mutation DMD gene lead loss protein dystrophin . Secondary inflammatory/immunological reaction contribute progressive course disease ( 1,2 ) . No curative therapy yet exist . Administration steroid establish medical treatment . Symptomatic measure also available , orthopaedic operation , treatment cardiomyopathy , advanced stage , home mechanical ventilation . In study involve experiment cell animal , Epigallocatechin-Gallate ( EGCG , major polyphenol green tea ) show neuroprotective effect . The neuroprotective mechanism action probably base several factor , include EGCG 's modulation several signal transduction pathway , influence expression gene regulate cell survival program cell death , well modulation mitochondrial function . The mdx mouse best-investigated animal model dystrophin-negative muscular dystrophy . Administration EGCG mdx mouse lead reduction proportion fibre necrose well less pronounced proliferation connective tissue muscle ( 3,4 ) , also improvement clinical symptom ( 5,6 ) . Therefore , investigator want investigate safety tolerance EGCG dosage 10mg/kg patient muscular dystrophy Duchenne type multicentre , prospective , double blind , placebo control , randomize pilot study .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Duchenne muscular dystrophy age 510 year ability walk without support inform consent parent another serious organic disease primary psychiatric neurological disease longterm intake livertoxic medicine</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>Epigallocatechin-Gallate</keyword>
	<keyword>Green tea extract</keyword>
</DOC>